Trials / Completed
CompletedNCT01423110
Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BYM338 in Patients With Sporadic Inclusion Body Myositis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy, safety and tolerability of BYM338 in patients with sporadic Inclusion Body Myositis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BYM338 | |
| BIOLOGICAL | Placebo |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2012-05-01
- Completion
- 2012-05-01
- First posted
- 2011-08-25
- Last updated
- 2020-12-17
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01423110. Inclusion in this directory is not an endorsement.